Studies long-term health of people with Down syndrome after leukemia treatment
Studies long-term health of people with Down syndrome treated for acute leukemia.
Key facts
- Who runs it
- Children's Oncology Group
- Where
- Akron, Albany, Ann Arbor, Atlanta, Augusta, Austin, Baltimore, Birmingham, Buffalo, Chapel Hill, Chicago, Cleveland, Columbia, Columbus, Dallas, Dayton, Detroit, Fargo, Fort Myers, Fort Worth, Grand Rapids, Greenville, Hackensack, Hollywood, Honolulu, Houston, Jackson, Jacksonville, Kalamazoo, Kansas City, Knoxville, Las Vegas, Madera, Madison, Marshfield, Memphis, Milwaukee, Minneapolis, Nashville, New Haven, Oakland, Oklahoma City, Omaha, Orlando, Pensacola, Philadelphia, Phoenix, Pittsburgh, Portland, Providence, Reno, Sacramento, San Antonio, San Diego, San Francisco, Seattle, Sioux Falls, Spokane, St Louis, Tampa, The Bronx, Wilmington, and Winston-Salem, United StatesSee the 72 sitesAlso in 1 other country, 1 site
- Trial code
- Registry title
- A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
- Status
- Recruiting
- People taking part
- 330 people, planned
- Started
- 30 Nov 2023
- Expected to end
- 30 Jun 2029
- Type of study
- Observational
- Treatments tested
- Biospecimen Collection
- Clinical Evaluation
- Neurocognitive Assessment
- Questionnaire Administration
- Survey Administration
- Record updated
- 25 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with Down syndrome who finished treatment for acute leukemia at least 36 calendar months ago. It studies their long-term health.
- Age
- Age 6 years up to under 40 years.
- Sex
- All sexes can join.
- Disease stage
- Down syndrome and past acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), including myeloid leukemia of Down syndrome. Relapse survivors can join if relapse treatment ended at least 36 calendar months ago and did not include a stem cell transplant. Life expectancy over 1 year.
- Earlier treatment
- All cancer treatment must have ended at least 36 calendar months before joining. Previous CAR T-cell therapy or other cellular cancer therapies are allowed.
- Biomarker or test result
- Down syndrome (trisomy 21, translocation or mosaicism) is required. Transient abnormal myelopoiesis alone is not enough.
Main reasons for not taking part
- Past hematopoietic stem cell transplant
- Another cancer before the ALL or AML diagnosis
- A new cancer after the ALL or AML diagnosis
- Patient or parent does not speak English or Spanish
- Parent or guardian cannot complete the required forms
This trial only enrols participants with Down syndrome. The registry sentence this rests on: A diagnosis of Down syndrome is required, and may include any of the three recognized types: trisomy 21 resulting from chromosomal nondisjunction (most common), translocation (the patient has 46 chromosomes, but all or part of an additional copy of chromosome 21 is attached to another chromosome), or mosaicism (trisomy 21 that is present in only a fraction of cells)
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Patients age >= 6 and < 40 years at the time of enrollment
- A diagnosis of Down syndrome is required, and may include any of the three recognized types: trisomy 21 resulting from chromosomal nondisjunction (most common), translocation (the patient has 46 chromosomes, but all or part of an additional copy of chromosome 21 is attached to another chromosome), or mosaicism (trisomy 21 that is present in only a fraction of cells)
- All patients must be DS-AL survivors (acute lymphoblastic leukemia [ALL] or acute myeloid leukemia [AML]); Note 1: Myeloid leukemia of Down syndrome (ML-DS) is included in the AML category above. Per the World Health Organization (WHO) definition of ML-DS, this diagnosis encompasses both myelodysplastic syndrome (MDS) and overt AML. Also, note that survivors of relapsed disease are eligible, so long as the patient otherwise meets eligibility criteria, i.e., treatment for relapse was completed at least 36 calendar months prior to enrollment and did not include stem cell transplant; Note 2: A diagnosis of transient abnormal myelopoiesis (TAM), also known as transient myeloproliferative disease (TMD), is not alone sufficient for inclusion in this study
- Patients must have been treated for ALL or AML; Note: History of COG therapeutic trial participation is not required. As a reminder ML-DS would be included under the AML category here above
- All cancer treatment (oral or intravenous) must have been completed at least 36 calendar months prior to enrollment
- Patients must have a life expectancy of > 1 year
- Patient and parent of subject must be either English or Spanish speaking. At least one parent or guardian must be able to read and write in English or Spanish; Note: Parents or guardians are responsible for completing all questionnaires, even in the case of subjects that are >= 18 years old
- All patients and/or their parents or legal guardians must sign a written informed consent
- All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Who cannot take part
- Patients with history of hematopoietic stem cell transplant (HSCT) are excluded; Note: Patients with previous chimeric antigen receptor T-cell (CAR T-cell) therapy, and other cellular cancer therapies can participate, as long as all other eligibility criteria are satisfied
- Patients with a history of cancers prior to their ALL or AML diagnosis are excluded. Patients that developed a subsequent malignant neoplasm following their ALL or AML diagnosis are also excluded; Note: Prior history of transient abnormal myelopoiesis is allowed, but is not sufficient for eligibility
- Patients whose parents or guardians are unable to complete the required forms are excluded
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 39 years old?
Where in United States
Also in 1 other country, 1 site
- Children's Hospital Medical Center of AkronAkron, United StatesContact: Erin Wright (principal investigator)Taking people
- Albany Medical CenterAlbany, United StatesContact: Lauren R. Weintraub (principal investigator)Taking people
- C S Mott Children's HospitalAnn Arbor, United StatesContact: Joshua W. Goldman (principal investigator)Taking people
- Children's Healthcare of Atlanta - Arthur M Blank HospitalAtlanta, United StatesContact: Karen E. Effinger (principal investigator)Taking people
- Augusta University Medical CenterAugusta, United StatesContact: Colleen H. McDonough (principal investigator)Taking people
- Dell Children's Medical Center of Central TexasAustin, United StatesContact: Shannon M. Cohn (principal investigator)Taking people
- Sinai Hospital of BaltimoreBaltimore, United StatesContact: Jason M. Fixler (principal investigator)Taking people
- Children's Hospital of AlabamaBirmingham, United StatesContact: Smita Bhatia (principal investigator)Taking people
- Roswell Park Cancer InstituteBuffalo, United StatesContact: Denise A. Rokitka (principal investigator)Taking people
- UNC Lineberger Comprehensive Cancer CenterChapel Hill, United StatesContact: Thomas B. Alexander (principal investigator)Taking people
- Lurie Children's Hospital-ChicagoChicago, United StatesContact: Lindsay F. Schwartz (principal investigator)Taking people
- University of Chicago Comprehensive Cancer CenterChicago, United StatesContact: Gabrielle Lapping-Carr (principal investigator)Taking people
- Cleveland Clinic FoundationCleveland, United StatesContact: Matteo M. Trucco (principal investigator)Taking people
- Rainbow Babies and Childrens HospitalCleveland, United StatesContact: Duncan S. Stearns (principal investigator)Taking people
- Prisma Health Richland HospitalColumbia, United StatesContact: Stuart L. Cramer (principal investigator)Taking people
- Nationwide Children's HospitalColumbus, United StatesContact: Mark A. Ranalli (principal investigator)Taking people
- UT Southwestern/Simmons Cancer Center-DallasDallas, United StatesContact: Ksenya Shliakhtsitsava (principal investigator)Taking people
- Dayton Children's HospitalDayton, United StatesContact: Jordan M. Wright (principal investigator)Taking people
- Children's Hospital of MichiganDetroit, United StatesContact: Alissa M. Martin (principal investigator)Taking people
- Sanford Broadway Medical CenterFargo, United StatesContact: Samuel J. Milanovich (principal investigator)Taking people
- Golisano Children's Hospital of Southwest FloridaFort Myers, United StatesContact: Emad K. Salman (principal investigator)Taking people
- Cook Children's Medical CenterFort Worth, United StatesContact: Donald T. Beam (principal investigator)Taking people
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's HospitalGrand Rapids, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
- BI-LO Charities Children's Cancer CenterGreenville, United StatesContact: Aniket Saha (principal investigator)Taking people
- Hackensack University Medical CenterHackensack, United StatesContact: Katharine R. Lange (principal investigator)Taking people
- Memorial Regional Hospital/Joe DiMaggio Children's HospitalHollywood, United StatesContact: Iftikhar Hanif (principal investigator)Taking people
- Kapiolani Medical Center for Women and ChildrenHonolulu, United StatesContact: Wade T. Kyono (principal investigator)Taking people
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer CenterHouston, United StatesContact: Omar Shakeel (principal investigator)Taking people
- UT MD Anderson Cancer CenterHouston, United StatesContact: Najat C. Daw (principal investigator)Taking people
- University of Mississippi Medical CenterJackson, United StatesContact: Amanda Strobel (principal investigator)Taking people
- Nemours Children's Clinic-JacksonvilleJacksonville, United StatesContact: Vibhuti Agarwal (principal investigator)Taking people
- Bronson Methodist HospitalKalamazoo, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
- Children's Mercy Hospitals and ClinicsKansas City, United StatesContact: Keith J. August (principal investigator)Taking people
- East Tennessee Childrens HospitalKnoxville, United StatesContact: Susan E. Spiller (principal investigator)Taking people
- Alliance for Childhood Diseases/Cure 4 the Kids FoundationLas Vegas, United StatesContact: Alan K. Ikeda (principal investigator)Taking people
- Summerlin Hospital Medical CenterLas Vegas, United StatesContact: Alan K. Ikeda (principal investigator)Taking people
- Sunrise Hospital and Medical CenterLas Vegas, United StatesContact: Alan K. Ikeda (principal investigator)Taking people
- University Medical Center of Southern NevadaLas Vegas, United StatesContact: Alan K. Ikeda (principal investigator)Taking people
- Valley Children's HospitalMadera, United StatesContact: Ruetima Titapiwatanakun (principal investigator)Taking people
- University of Wisconsin Carbone Cancer Center - University HospitalMadison, United StatesContact: Cathy A. Lee-Miller (principal investigator)Taking people
- Marshfield Medical Center-MarshfieldMarshfield, United StatesContact: Michelle A. Manalang (principal investigator)Taking people
- Saint Jude Children's Research HospitalMemphis, United StatesContact: Lisa Jacola (principal investigator)Taking people
- Children's Hospital of WisconsinMilwaukee, United StatesContact: Rachel A. Phelan (principal investigator)Taking people
- Children's Hospitals and Clinics of Minnesota - MinneapolisMinneapolis, United StatesContact: Michael K. Richards (principal investigator)Taking people
- University of Minnesota/Masonic Cancer CenterMinneapolis, United StatesContact: Karim T. Sadak (principal investigator)Taking people
- Vanderbilt University/Ingram Cancer CenterNashville, United StatesContact: Debra L. Friedman (principal investigator)Taking people
- Yale UniversityNew Haven, United StatesContact: Rozalyn L. Rodwin (principal investigator)Taking people
- Kaiser Permanente-OaklandOakland, United StatesContact: Aarati V. Rao (principal investigator)Taking people
- UCSF Benioff Children's Hospital OaklandOakland, United StatesContact: Karen R. Rabin (principal investigator)Taking people
- University of Oklahoma Health Sciences CenterOklahoma City, United StatesContact: Rene Y. McNall-Knapp (principal investigator)Taking people
- Children's Hospital and Medical Center of OmahaOmaha, United StatesContact: Jill C. Beck (principal investigator)Taking people
- University of Nebraska Medical CenterOmaha, United StatesContact: Jill C. Beck (principal investigator)Taking people
- Nemours Children's HospitalOrlando, United StatesContact: Vibhuti Agarwal (principal investigator)Taking people
- Nemours Children's Clinic - PensacolaPensacola, United StatesContact: Jeffrey H. Schwartz (principal investigator)Taking people
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Sogol Mostoufi-Moab (principal investigator)Taking people
- Phoenix Childrens HospitalPhoenix, United StatesContact: Alexandra M. Walsh (principal investigator)Taking people
- Children's Hospital of Pittsburgh of UPMCPittsburgh, United StatesContact: Jean M. Tersak (principal investigator)Taking people
- Oregon Health and Science UniversityPortland, United StatesContact: Susan J. Lindemulder (principal investigator)Taking people
- Rhode Island HospitalProvidence, United StatesContact: Bradley DeNardo (principal investigator)Taking people
- Renown Regional Medical CenterReno, United StatesContact: Alan K. Ikeda (principal investigator)Taking people
- University of California Davis Comprehensive Cancer CenterSacramento, United StatesContact: Marcio H. Malogolowkin (principal investigator)Taking people
- University of Texas Health Science Center at San AntonioSan Antonio, United StatesContact: Shafqat Shah (principal investigator)Taking people
- Rady Children's Hospital - San DiegoSan Diego, United StatesContact: William D. Roberts (principal investigator)Taking people
- UCSF Medical Center-Mission BaySan Francisco, United StatesContact: Karen R. Rabin (principal investigator)Taking people
- Seattle Children's HospitalSeattle, United StatesContact: Sarah E. Leary (principal investigator)Taking people
- Sanford USD Medical Center - Sioux FallsSioux Falls, United StatesContact: Jordan Fritch-Hanson (principal investigator)Taking people
- Providence Sacred Heart Medical Center and Children's HospitalSpokane, United StatesContact: Judy L. Felgenhauer (principal investigator)Taking people
- Washington University School of MedicineSt Louis, United StatesContact: Robert J. Hayashi (principal investigator)Taking people
- Saint Joseph's Hospital/Children's Hospital-TampaTampa, United StatesContact: Don E. Eslin (principal investigator)Taking people
- Montefiore Medical Center - Moses CampusThe Bronx, United StatesContact: Alice Lee (principal investigator)Taking people
- Alfred I duPont Hospital for ChildrenWilmington, United StatesContact: Vibhuti Agarwal (principal investigator)Taking people
- Wake Forest University Health SciencesWinston-Salem, United StatesContact: Sarah Supples (principal investigator)Taking people
About the trial
What the trial wants to find out
This study attempts to learn more about the health of persons with Down syndrome after treatment for acute leukemia. Children with Down syndrome are at increased risk for side effects during treatment for acute leukemia, but it is unclear of their risk for long-term effects of cancer treatment. By learning more about the factors that may contribute to chronic health conditions and long-term effects after treatment for leukemia in persons with Down syndrome, clinical practice guidelines for survivorship care can be developed to help improve their quality-of-life.
The group in the trial
- Observational (biospecimen collection, clinical evaluation)
Patients undergo an optional saliva/buccal swab in part 1 and clinical assessment in part 2 of the study. Patients with DS-ALL may then undergo blood sample collection and neurocognitive assessment in part 3 of the study.
Treatment: Biospecimen Collection, Clinical Evaluation, Neurocognitive Assessment, Questionnaire Administration, and Survey Administration
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Chronic Health Conditions in Down Syndrome-Associated Acute Leukemia: The Down Syndrome Phenotyping Acute Leukemia Study in Survivors (DS-PALS Survivors)
- Plain-language title
- Studies long-term health of people with Down syndrome after leukemia treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05702645, who can take part
- Publications
- Record updated
- 25 August 2026